The Inc. 500, which ranks the fastest growing U.S. privately held companies, announced that DSG reached No. 82 in the nation, making it the fastest growing privately held company in the Philadelphia area. As an Inc. 500 honoree, DSG shares a prestigious pedigree with such notable companies as Intuit, Microsoft, and Oracle.
According to the Inc. 500, DSG is leading the move forward on clinical trials in the healthcare arena, providing electronic data capture (EDC) for clinical trial data collection and management on a global basis. DSG is accelerating the change from paper data collection and management to the highly efficient electronic data system of eCaseLink™, making the transition seamless, efficient and cost-effective.
“We’re very excited to be recognized by the Inc. 500, not just for ranking DSG No. 82 on the list, but for spotlighting our leadership in the clinical trial arena,” said Tony Varano, CEO, DSG, Inc.
Recently, DSG’s eCaseLink™ system helped Human Genome Sciences to reach a landmark Phase 3 trial success for BENLYSTA™, which has the potential to become the first new approved drug in decades to give hope to people living with systemic lupus. The clinical trial data management and collection process was essential in this massive and highly complex Phase 3 trial. Key to the success of the trial was DSG’s technology leadership and project management, which ensured that subject data was accurate, complete and timely.
While DSG looks relentlessly forward, its success stems from age-old business sense. Tony Varano, CEO, DSG, “sure our success is driven by pioneering EDC software, but firmly held, timeless values actually drive our growth. We understand that change is good, it keeps us sharp. We don’t take successes for granted, we earn them one at a time. We have a real passion for what we do and we work hard at it. We’re married to our customers’ work as if it is our own. Finally, because we’re privately owned, we work very smart and lean with our expenditures. The result is dynamic, yet carefully managed growth.”
Risankizumab outperforms ustekinumab in treating moderate-to-severe Crohn’s disease